Alcidion Group Limited · ASX:ALC
Alcidion — H1 2026 Earnings Presentation
36 slides from Alcidion's earnings presentation, Feb 26, 2026
Slide 1: H1 FY26 Results Presentation
H1 FY26 Results Presentation February 2026
Slide 2: Disclaimer
Disclaimer The information contained in this document (“Document”) has been prepared by Alcidion Group Limited ACN 143 142 any change in expectations in relation to any such statements or any change in events, conditions or circumstances 410 (referred to as “Alcidion” or “Company”). This Document is
Slide 3: Snapshot & Miya Precision Platform
01. Snapshot & Miya Precision Platform
Slide 4: Company Overview
Company Overview A leading global health informatics platform modernising health systems at scale 400+ 100+ 50k+ Global health informatics platform enhancing and replacing outdated, manual and legacy systems to meet modern day demands in healthcare. Hospitals Healthcare Clients Beds across the UK, A
Slide 5: Investment Highlights
Investment Highlights Significant sales momentum following a record H1 FY26 and a defined and executable growth strategy across both current and new markets Mission-critical health Diversified and long-term Attractive unit economics with Capital light business model informatics platform providing a
Slide 6: Strong Global Footprint
Strong Global Footprint Growing global operations diversified across attractive target markets 108 Health Services Global footprint across the UK, Australia and NZ. 10 Health Systems 100+ clinical system 447 Hospitals implementations. Canada Exploring New Markets 11 Health Systems A platform approac
Slide 7: Alcidion: Solving critical healthcare challenges
Alcidion: Solving critical healthcare challenges Hospital Bed icon Core Admin / clinical staff lack Long-term patient medical Disparate systems don’t Hospital executives lack Ability to safely monitor problems real-time visibility on bed history is incomplete, interoperate; challenges real-time visi
Slide 8: What is Miya Precision?
What is Miya Precision? An unrivalled clinicial and administration platform Designed for AI Miya Precision has been designed for AI, enabling data consolidation to deliver insights to clinicians, whilst maintaining patient data security Digital Clinical Workflow Operate in Real-Time Miya Precision e
Slide 9: Smarter Solutions for Clinicians
Smarter Solutions for Clinicians Meeting the daily needs of clinicians, by clinicians Solutions Powering Smarter Care Patient Flow Emergency Modular EPR Virtual Care Integrated At the core of Alcidion’s solutions & Command Emergency Modular cloud- Virtual care and Care Record is our FHIR-based inter
Slide 10: Patient Journey with Miya Precision
Patient Journey with Miya Precison A value proposition (module) at every point of care 8. Miya Record 14. Miya Command • A single, longitudinal view of a patient’s healthcare • Real-time access to 1. Miya Emergency journey across providers consolidated data 7. Smartpage • Effective care collaboratio
Slide 11: H1 FY26 Highlights
02. H1 FY26 Highlights EXECUTIVE SUMMARY
Slide 12: H1 FY26 – Financial Highlights
H1 FY26 – Financial Highlights Growth across key financial metrics $25.5M $31.1M $23.6M $4.2M ($2.6M) H1 FY26 new and renewal H1 FY26 revenue ARR2 (as at 31 Dec-25) Underlying EBITDA3 Operating cash outflow TCV Up 44% on pcp1 Up 9% on 30 Jun-25 Up 29% on pcp Up 675% or an Improvement of $1.7M improv
Slide 13: H1 FY26 – Operational Highlights
H1 FY26 – Operational Highlights Continuing sales momentum with flagship expansion wins › Expanded contracts: › Sept-25: North Cumbria NHS Trust2 (UK): Expansion via partnership with Mizaic (electronic document management) › Nov-25: Leidos Australia (AUS): Expansion to include additional Miya Precis
Slide 14: Financial Results
03. Financial Results H1 FY26 RESULTS
Slide 15: Profit & Loss
Profit & Loss Growth in recurring revenue driving material EBITDA uplift & maiden H1 NPAT Profit & loss (A$000) H1’25 H1’26 % change › 44% increase in revenue versus the PCP, including: Recurring revenue: › 41% growth in recurring revenue driven by full year impact of new Product – M&S2 + annual lic
Slide 16: Revenue Dashboard
Revenue Dashboard Sustainable growth underpinned by long-term, contracted and high-quality recurring revenue 40.4 40.8 37.1 H1 vs H2 34.4 21.4 23.1 Geographical 18.0 Revenue 21.5 Split (%) 25.5 Split ($M) $25.5M 25.5 48% 52% H1’26 19.0 19.1 17.6 UK ANZ 12.9 FY22 FY23 FY24 FY25 H1'26 6.4 41% 39% 29%
Slide 17: Our revenue model
Our revenue model Sustainable growth underpinned by long-term, contracted and high-quality recurring revenue Core Product Platform Solutions Patient Flow Virtual Care Integrated Care Record Modern Modular EPR Operations Centre Clinical Workflow Specialised Care Revenue Capital License Annual subscri
Slide 18: Balance Sheet
Balance Sheet Significant balance sheet flexibility to pursue growth opportunities Balance sheet ($000) 30 Jun 25 31 Dec 25 › $14.2m cash and no debt as of 31 December 2025 Cash & cash equivalents 17,697 14,195 › $6.5M higher than at Dec 24 and $3.5M lower than at June 25 Trade & other receivables 3
Slide 19: Cashflow
Cashflow H1 impacted by short-term working capital movements which will unwind in H2 Cash flow ($000) H1’25 H1’26 › Receipts from customers increase $1.6M on PCP Receipts from customers 15,342 16,957 › H1 receipts historically lower than H2 receipts, we expect a material Payments to supplier and emp
Slide 20: Accelerating customer wins
04. Accelerating customer wins
Slide 21: Sales momentum accelerating
Sales momentum accelerating… $97m+ (excl UHSx) of new and renewal TCV won over past 18 months Average contract term 5-10 years Jul 2024 Nov 2024 Feb 2025 Sept 2025 Q2 FY26 Hume Rural Health NALHN Hywel Dda North Cumbria NHS Lanarkshire NHS New customer New customer New customer Existing customer Exi
Slide 22: Notable Extension / Expansion Wins
Notable Extension / Expansion Wins Continued ability to expand functionality with customers over time leading to TCV uplift Leidos Australia / ADF (AUS) North Cumbria NHS Trust (UK) › 3rd expansion to the original contract to June 2028, › Expanded to include third-party partner, Mizaic with extensio
Slide 23: Further EPR Validation: UHSussex
Further EPR Validation: UHSussex Selected as preferred supplier by University Hospitals Sussex for new EPR platform solution Preferred Supplier - Overview Indicative Contract Terms › Selected following a competitive tender process › Deploy Miya Precision core modules and Better medications managemen
Slide 24: Successful Deployments in H1 FY26
Successful Deployments in H1 FY26 Product Implementation delivery have always been a strength for Alcidion University Hospitals Southampton (UK) North Adelaide Local Health Network (AUS) › Deployed Miya Emergency – second customer to › In Q1 FY26, ‘live’ with Miya Flow, Access and deploy module and
Slide 25: Land and Expand Strategy Driving TCV Uplift
Land and Expand Strategy Driving TCV Uplift Delivering tangible examples of strategy execution… 1 2 3 4 Leidos Australia (Aus) North Cumbria (UK) South Tees (UK) Hume (Aus) › Q2’22 – 6-year contract to deliver › Q3’25 – 10-year contract for EPR › Q2’20 – 5-year contract for several › Q1’25 – New con
Slide 26: Miya Precision customers nominated for 2026 HSJ Digital Awards
Miya Precision customers have been nominated for 6 prestigious awards at the 2026 HSJ Digital Awards Outstanding Achievement in EPR Driving Virtual Wards and Digital Team Implementation and Optimisation Hospital at Home Through Digital of the Year "Clinical Excellence in the Digital "Transforming PO
Slide 27: Miya Precision recognised as a leading solution for healthcare modernisation
Miya Precision has been recognised as a leading solution for healthcare modernisation “In the emergency and prehospital segment, Alcidion Miya Precision is rated #1 across Clinical & Operational Effectiveness, Interoperability, Data & Innovation and Partnership, Value & Strategic Alignment, emphasis
Slide 28: Growth Strategy and Outlook
05. Growth Strategy and Outlook
Slide 29: Growth Pillars Support a Global Platform
Growth Pillars Support a Global Platform Multi-focus approach combining growth within existing customers, expansion in existing territories and attractive new markets and geographies Organic Growth 1 Scale Existing Markets 2 Evolve Product Functionality 3 Expand into New Geographies & Adjacencies •
Slide 30: Scale in Existing Markets
Scale in Existing Markets Recent success in Australia highlights the material opportunity still existing in Australia which is complemented by larger UK opportunities Australia UK & NHS markets Patient Flow England › Reduce incidence of bed blockage with effective patient flow tools › In June 2025,
Slide 31: Evolve Product Functionality
Evolve Product Functionality Bringing generative AI to healthcare Example Miya AI capability: Miya Scribe being Advancing product innovation has always been a core used for population of clinical documentation part of the Miya Precision platform. We solve complex healthcare challenges, providing int
Slide 32: Expanding into New Geographies
Expanding into New Geographies Priority targets selected based on alignment to existing Alcidion markets with smaller investment required to gain entry Canada Middle East (Saudi Arabia, UAE) Win and Build Entry via Pilot Partner Steps taken to date: Steps taken to date: › Contracted experienced Cana
Slide 33: Outlook & Guidance
Outlook & Guidance Momentum continuing into 2H FY26 underpinned by preferred supplier status, high contracted revenue and a maturing pipeline of expansion & new opportunities Outlook FY26 Guidance (underpinned by the Outlook) • As of 31 Dec-25, contracted & renewal revenue to be recognised in • Reve
Slide 34: Appendix
06. Appendix
Slide 35: Alcidion Board – Deep Healthtech Expertise
Alcidion Board – Deep Healthtech Expertise Rebecca Wilson Kate Quirke Daniel Sharp Andrew Way William Smart Non-executive Chair Group Managing Director/ Non-executive Director Non-executive Director Non-executive Director Chief Executive Officer Experienced company director with 25+ years of digital
Slide 36: Alcidion
A @ ALCIDION